Mission
To ensure that our therapies have their greatest impact by always focusing on the patient, and following the science to run impactful and high-quality clinical development.
Pipeline
Linsitinib is an oral therapy being developed for thyroid eye disease (TED) that will ease the treatment burden for patients, caregivers, and physicians.
